Science News
from research organizations

Experimental post-exposure antiviral treatment may protect humans from Ebola virus

Date:
August 25, 2015
Source:
The Lancet
Summary:
For the first time, physicians have demonstrated that antiviral-based therapies have the potential to protect humans from the deadly Ebola virus. The report describes a case-series of eight British health-care workers who were evacuated to the Royal Free Hospital in London, UK after possible accidental exposure to Ebola virus in Sierra Leone between January and March 2015.
Share:
FULL STORY

For the first time, UK physicians have demonstrated that antiviral-based therapies have the potential to protect humans from the deadly Ebola virus. The report, published in The Lancet Infectious Diseases journal, describes a case-series of eight British health-care workers who were evacuated to the Royal Free Hospital in London, UK after possible accidental exposure to Ebola virus in Sierra Leone between January and March 2015.

Four of the health-care workers were considered to have been at significant risk of exposure to Ebola from needlestick injuries and were given post-exposure prophylaxis (PEP) with the antiviral drug favipiravir (Toyama Chemical Company [1]), with or without monoclonal antibodies (similar to ZMapp). The other four workers had exposure that was not the result of a sharps injury, and were judged to be at lower risk. They were not given PEP, but were managed by watchful waiting.

None of the health-care workers went on to develop Ebola. All eight healthcare workers remained healthy throughout the 42 day follow-up, with no signs of disease or detectable levels of virus in their blood. The treatment regimen was well tolerated with no serious adverse events reported.

"It is possible that none of these health-care workers were infected with Ebola virus. Therefore, we cannot know for sure whether or not post-exposure prophylaxis prevented the onset of Ebola-virus disease," says lead author Dr Michael Jacobs from the Royal Free NHS Foundation Trust, London, UK. "However, two of the workers had needlestick injuries contaminated with fresh blood from patients with Ebola virus disease putting them at very high risk of transmission." 

The risk of Ebola infection for healthcare workers in west Africa is high. By 5 August, 2015, 880 out of 27862 cases of Ebola were reported in healthcare workers. Yet, for doctors and nurses caring for Ebola patients there are no guidelines to quantify exposure risk, and until now, any evidence that PEP may be beneficial in humans.

According to Dr Jacobs, "We are excited to publish the first report of an antiviral-based postexposure treatment against Ebola-virus infection in humans. We believe this work justifies further study of this postexposure treatment to protect health-care workers accidentally exposed to Ebola virus in the field. What is more, a similar approach to treat household contacts of Ebola cases may work to prevent a major route of spread during an epidemic." 

The authors conclude by calling for standardised guidelines about transmission risk and management after potential exposure to be urgently developed and adopted as they have been for many other infections such as HIV and hepatitis B virus.

Writing in a linked Comment, Professor Mark Mulligan and Dr Paul Siebert from Emory University in the USA said, "A needed next step is the development of a consensus risk determination algorithm devised by an expert panel, drawing upon all available evidence, endorsed by health organisations, and disseminated to the field. The algorithm could be accompanied by a chart abstraction and case report form to standardise and organise data gathering. These data for recognised exposures could be collated and analysed for an international registry."

This study was funded by the Royal Free London NHS Foundations Trust.

[1] The antiviral drug favipiravir is approved in Japan for treating severe flu and has shown efficacy against the Ebola virus in vitro and in mice.


Story Source:

Materials provided by The Lancet. Note: Content may be edited for style and length.


Journal Reference:

  1. Michael Jacobs, Emma Aarons, Sanjay Bhagani, Ruaridh Buchanan, Ian Cropley, Susan Hopkins, Rebecca Lester, Daniel Martin, Neal Marshall, Stephen Mepham, Simon Warren, Alison Rodger. Post-exposure prophylaxis against Ebola virus disease with experimental antiviral agents: a case-series of health-care workers. The Lancet, 2015 DOI: 10.1016/S1473-3099(15)00228-5

Cite This Page:

The Lancet. "Experimental post-exposure antiviral treatment may protect humans from Ebola virus." ScienceDaily. ScienceDaily, 25 August 2015. <www.sciencedaily.com/releases/2015/08/150825205906.htm>.
The Lancet. (2015, August 25). Experimental post-exposure antiviral treatment may protect humans from Ebola virus. ScienceDaily. Retrieved May 23, 2017 from www.sciencedaily.com/releases/2015/08/150825205906.htm
The Lancet. "Experimental post-exposure antiviral treatment may protect humans from Ebola virus." ScienceDaily. www.sciencedaily.com/releases/2015/08/150825205906.htm (accessed May 23, 2017).

RELATED STORIES